News

Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the Agency’s evaluation time from 210 to 150 days. “The MAA submission for patisiran represents another important

Regeneron and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer. Expression of HPV oncoproteins contributes to the development

Vraylar (cariprazine) is an oral and once daily atypical antipsychotic secured approval for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I

Published in draft guidance, the enforcement priorities are expected to keep a check on certain homeopathic drugs that can be harmful and have no proven medical benefits. The

Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate

SKs are non-cancerous skin growths that affect more than 83 million American adults and can be an aesthetic skin concern. SKs tend to increase in size and number

The phase 3 Keynote-061 trial assessing Keytruda as a second-line treatment for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma did not achieve its primary endpoint of

The drug-discovery partnership, which will last for five-years, will be focused on Messenger RNA (mRNA) translation. According to Cancer Research UK, mRNA translation, which is the cellular process of assembling proteins,

Actus will benefit from AskBio’s ability to generate organ and tissue-specific single-stranded and self-complementary genome containing adeno-associated virus vectors (AAVs), the company’s manufacturing platform and managements’ experience progressing